VRTX logo

Vertex Pharmaceuticals Incorporated

VRTX
Healthcare|Biotechnology|US
$547.09
+4.59 (+0.85%)
DCF Value
$349.13
Tangible Book / Share
$39.31
Graham Number
$170.60
Cash / Share
$24.87

About

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Stock Price

+31.4%(1Y)
1M
+8.7%
3M
+10.3%
6M
+27.3%
YTD
+20.7%
1Y
+29.9%
3Y
+45.1%
5Y
+184.6%

Pipeline Summary

294 total trials
92
Phase 1
88
Phase 2
96
Phase 3
11
Phase 4
Completed: 224Terminated: 21Recruiting: 13Not Yet Recruiting: 6Withdrawn: 5Active: 15Approved: 4By Invitation: 5Unknown: 1

Active Trials (28)

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT06619860Diabetic Peripheral Neuropathic Pain
Phase 2Recruiting
Enrollment: 300 participants
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649Sickle Cell Disease
Phase 3Active
Enrollment: 13 participants
Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
NCT07868926Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 1Recruiting
Enrollment: 8 participants
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older
NCT06460506Cystic Fibrosis
Phase 3Active
Enrollment: 50 participants
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
NCT07437105Cystic Fibrosis
Phase 1Recruiting
Enrollment: 160 participants

BioScore

8.2/10
Strong Buy

Key Facts

Market Cap$138.67B
Employees6,400 (+5% YoY)
CEOReshma Kewalramani
IPO DateJul 24, 1991
Beta0.32
52-Week Range$410.5 – $568.67
Avg Volume1,318,485
ExchangeNASDAQ
Websitevrtx.com

Ownership

Float99.8%
Shares Outstanding253.5M

Recent Insider Trades

Brennan Daniel J.AWARD
Oct 20, 2026795 shares @ $503.47
Brennan Daniel J.OTHER
Oct 20, 20260 shares
SACHS BRUCE IAWARD
Oct 15, 202692.694 shares
Garber Alan MAWARD
Oct 15, 202629.272 shares
van Grunsven JasperAWARD
Sep 8, 20268,682 shares

Peers

ALNYAlnylam Pharmaceuticals, Inc.
$20.89B
BBIOBridgeBio Pharma, Inc.
$14.47B
BEAMBeam Therapeutics Inc.
$2.73B
BMRNBioMarin Pharmaceutical Inc.
$10.85B
CRSPCRISPR Therapeutics AG
$4.86B
IONSIonis Pharmaceuticals, Inc.
$6.55B
NTLAIntellia Therapeutics, Inc.
$1.59B
PTCTPTC Therapeutics, Inc.
$5.47B
Data last updated: Nov 9, 2026, 04:40 AM